LONDON (Alliance News) - Amryt Pharma PLC on Tuesday said it signed four distribution deals for its cholesterol disorder drug Lojuxta across the Middle East.
The biopharmaceutical company said it secured contracts with Al Hafez Trading Establishment in Kuwait, Ebn Sina Medical in Qatar, Muscat Pharmacy & Stores in Oman, and Goro Healthcare in United Arab Emirates and Bahrain.
The recent expansion of licence agreements has increased the total number of addressable patients in Amryt's territories by around 25%. The company now distributes Lojuxta across Europe, the Middle East, Turkey, Israel, Russia, the Commonwealth of Independent States, and the Balkan states.
In 2017, Amryt generated revenue of EUR11.9 million from sales of Lojuxta.
"Driving Lojuxta's growth in new and existing territories is a core focus for Amryt in 2018," said Chief Executive Joe Wiley. "We remain in discussions with other potential distribution partners as we continue to grow our network and market reach for Lojuxta."
Shares in Amryt were trading 1.5% higher at 17.10 pence each on Tuesday.
